President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
Clinical Research50-Year Medalist Study
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Howard Wolpert, M.D.

Research Summary

The focus of my research and clinical activities in the Section of Adult Diabetes at the Joslin Diabetes Center relate to the use of technology in intensive diabetes management.

Related to this, I established and direct the Insulin Pump & Continuous Glucose Monitoring Programs at the Joslin Clinic, and have been principal investigator in several multi-center randomized controlled trials, including the Juvenile Diabetes Research Foundation (JDRF) CGM trial, which was the first study to demonstrate the efficacy of  CGM. On the basis of the trial results (which were published in the New England Journal of Medicine) several major health insurers broaden coverage for use of CGM by adults with type 1 diabetes, setting the stage for widescale adoption of this technology.

My group achieved the best outcome data of the ten centers participating in this trial and was honored with a Performance Award from the JDRF.

The Joslin CGM program incorporates a clinical pathway for training patients on CGM, and to date over 570 adults with type 1 diabetes had been started on CGM at the Joslin. My other activities related to diabetes technology  include membership of the Endocrine Society/European Society of Endocrinology committee developing CGM practice guidelines (was primary writer of recommendations for outpatient use of CGM in adults).

In addition, I  am one of two foreign members of the Scientific Advisory Board of the European Union-funded academic/industry collaborative on diabetes technology.

Page last updated: September 19, 2019